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Abstract
Background: Warthin's tumor is a benign monomorphic adenoma with unclear origin that almost
occur exclusively in the parotid gland. Etiology of Warthin's tumor as well as its malignant potential
are still unclear. Therefore immunohistochemical assessment of Warthin's tumor may be useful to
detect its origin or its malignant transformation potential.
Aims and objectives: The present study aims to investigate the immunohistochemical
expression of murine double minute-2 (mdm-2), p27Kip1 and B cell lymphoma-2 (bcl-2) in Warthin's
tumor of parotid gland and also to clarify the role of these proteins in the behavior of that tumor.
Methods: Twenty paraffin blocks of cases previously diagnosed as Warthin's tumor were collected
for immunohistochemical staining with primary antibodies against mdm-2, p27Kip1 and bcl-2 using
streptavidin-biotin immunoperoxidase staining system.
Results: All cases showed immunopositivity for mdm-2 and p27Kip1 while 18/20 showed bcl-2
immunopositivity. Both layers of the neoplastic epithelial cells that line the cystic spaces showed
immunopositivity with all antibodies used. Goblet cells were mdm-2 immunonegative while
myoepithelial cells were p27Kip-1 immunonegative. Areas of epithelial proliferation that formed buds
were p27Kip-1 and bcl-2 immunopositive.
Conclusion: Mdm-2 played a tumor-suppressor role that might be implicated with the benign
behavior of Warthin's tumor. The mutual expression of both p27Kip1 and bcl-2 suggested a
protective role of these slowly proliferating cells from apoptosis to maintain their survival and
elevated bcl-2 expression offers a significant protection against p27Kip1-mediated apoptosis.
Background
Warthin's tumor is classified as a benign monomorphic
adenoma of salivary gland that occurs exclusively in the
parotid gland. Its etiology is still controversial; some
authors suggested a bi-layered excretory ductal structure of
the neoplastic epithelium in Warthin's tumor, as a result
of hyperplastic process of the glandular epithelium that
interacts with the excessive lymphoid tissue of the stroma
[1]. Some authors consider it as a tumor like condition,
not a monomorphic adenoma as it resulted from the pro-
liferation of salivary gland ductal cells that were
entrapped in parotid lymph nodes during embryonal life
[2]. Although, other investigators detected, rare, histolog-
ical change from Warthin's tumor to mucoepidermoid
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carcinoma that may be implicated in squamous or goblet
cell metaplasia of epithelial cells. It is considered that the
neoplastic cells of Warthin's tumor acquire malignant
genotypes simultaneously with this dual differentiation
leading to the formation of mucoepidermoid carcinoma,
mostly low grade [3,4]. Therefore immunohistochemical
assessment of Warthin's tumor may be useful to detect its
origin or its malignant transformation potential.
Mdm2 is identified as an evolutionary conserved gene and
as a dominant transforming oncogene on the long arm of
the chromosome twelve. It encodes a number of alterna-
tively spliced mRNAs that give rise to proteins ranging in
size from 40 kilo Dalton (KDa) to 90 KDa: p90, p57–58,
p74, p76 and p85 [5].
Mdm2 performs several functions; some of them are
related to p53. By binding to p53, mdm2 has at least two
functions: first it can target p53 for ubiquitin-degradation.
The process of ubiquitination is subjected to a feedback
loop as mdm2 protein binds to p53 to be degraded. This
lowers the concentration of p53 and reduces transcription
of mdm2 gene, closing the feedback loop and allowing
p53 levels to rise again [6].
Second, mdm2 can also bind to the acidic activation
domain of p53, concealing it from the transcriptional
machinery i.e. blocking the ability of p53 to be recruited
into active transcriptional complexes [7].
P90, the major product of mdm2, is now considered to
form a tight complex with both the wild-type and mutant
p53 tumor-suppressor gene product and inactivate wild-
type p53 function by masking the N-terminal acidic trans-
activating domain of p53 protein, indicating that abnor-
malities of mdm2 gene may be closely associated with
tumorigenesis and/or tumor development [8].
The smaller mdm2 protein, p76, increases the level of p53
by blocking the function of p90. Therefore, although, p90
and p57 bind to p53 and inhibit its nuclear accumulation,
p74/76 can stabilize p53 by inhibiting the ability of p90
to stimulate its degradation without affecting the p90/p53
interaction [8].
Mdm2 may have a role in preventing apoptosis, either
through inactivation of p53 or through some other mech-
anism independent of p53 [6]. On the other hand, it may
down-regulate the anti-apoptotic protein Bcl-2 [9].
Inactivation of mdm2-induced G0/G1 arrest may contrib-
ute to tumor development [10], hence, mdm2 appears to
play dual roles, as a tumor suppressor and as an oncogene,
depending on the levels of mdm2 being expressed in the
cell [11].
Mantesso et al [12] and Schlott et al [13] reported that
mdm2 gene seems to be an early event related to the
development of benign salivary gland tumors and play a
part in tumor progression in salivary gland neoplasms.
P27Kip1, a member of kinase inhibitory protein (KIP) fam-
ily was identified as an inhibitory protein induced by tans-
forming growth factor-β (TGF-β) that played an important
role in differentiation, senescence and cellular responses
to negative growth-regulatory cytokines and to DNA dam-
age and hence plays an essential role in the proliferative
arrest that accompanies differentiation as well as is inte-
grally involved in ensuring an orderly progression
through the cell cycle [14].
Levels of p27Kip1 are high in normal quiescent cells (G0/
G1 cells) but decrease in cycling cells, rapidly after
mitogenic stimulation, when it gets sequestered into
excess cyclin-cyclin-dependent kinase complexes. It
remains low thereafter in actively proliferating cells [15].
Different mechanisms appear to regulate apoptosis in
resting or cycling cells; deregulated activation of cyclin-
dependent kinases results in apoptosis in resting cells,
whereas cyclin-dependent kinase inhibition induces
apoptosis in cycling cells. Therefore, apoptosis may result
from activation of pathways that promote apoptosis upon
inappropriate expression of cell cycle regulatory mole-
cules. P27Kip1 functions at a critical switch point where
growth arrest is followed either by differentiation or apop-
tosis [16].
Apoptosis is modulated by several proteins or antigens
such as the bcl-2 family and p53. Regulation of apoptosis
is dependent on interactions between effector and sup-
pressor molecules. Deregulation of the genes controlling
apoptosis may contribute to the process of tumourigene-
sis by reducing the rate of cell death and allowing the
accumulation of other genetic defects [17].
Bcl-2 emerged as a new type of proto-oncogene that sup-
presses cell death rather than stimulating proliferation.
However, it does not inhibit apoptosis occurring in all cir-
cumstances as it failed to block apoptosis induced by cyto-
toxic T-lymphocytes [18].
The involvement of bcl-2 in p53-induced apoptosis was
first suggested by the observation that p53-induced cell
death can be prevented by bcl-2 expression. Wild-type
p53-dependent apoptosis occurs at least partly through its
suppressive effect on bcl-2 expression or its function. Sup-
port for this has come from in vitro studies of lymphoid
cells where ectopic p53 was shown to down-regulate
endogenous bcl-2 expression while simultaneously
increasing the expression of bax [19].Diagnostic Pathology 2009, 4:14 http://www.diagnosticpathology.org/content/4/1/14
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The aim of the present study is to investigate the immuno-
histochemical expression of mdm-2, p27Kip1 and bcl-2 in
Warthin's tumor of parotid gland and also to clarify the
role of these proteins in the behavior of that tumor.
Method
Tissue samples
Twenty paraffin blocks of cases previously diagnosed as
Warthin's tumor were collected from the archives of the
Oral Pathology Department, Faculty of Dentistry, Ain
Shams University. Haematoxylin and Eosin stained sec-
tions were prepared for each specimen to confirm the
diagnosis. From each of the selected paraffin blocks three
sections of 4 μm thick were cut and mounted on positively
charged slides (Biogenex Corp, California, USA) for
immunohistochemical staining.
Reagents
Monoclonal antibodies against mdm2, p27Kip1 and bcl-2
were used. These antibodies recognized their correspond-
ing proteins in paraffin-embedded sections. Monoclonal
IgG-Kappa antibody against mdm2 was purchased from
(Zymed Laboratories Inc., USA). It recognizes epitope
located within the amino acid 26–169 of the human
mdm2 protein. While monoclonal antibody against
p27Kip1 was purchased from (DAKO Corporation, USA)
and monoclonal antibody against bcl-2 was purchased
from (Zymed Laboratories Inc., USA).
A streptavidin-biotin immunoperoxidase staining system
was used for immuno-detection. It included the following
reagents:
￿ Monoclonal Linking Reagent: biotinylated anti-
mouse immunoglobulin
￿ Streptavidin Enzyme Label: horseradish peroxidase-
conjugated streptavidin
￿ Buffered Substrate: Hydrochloric acid (HCl) buffer,
pH 7.5
￿ Enzyme Substrate: 0.6% hydrogen peroxide
￿ DAB Chromogen Concentrate: 3.3' diaminobenzi-
dine in chromogen solution
￿ Buffered Wash Solution: phosphate buffered saline
(PBS), 0.1 mol/l, pH 7.4 ± 2
The detection systems were purchased from DAKO Cor-
poration, USA and Zymed Laboratories Inc., USA.
The retrieval solution was purchased from BioGenex,
USA.
Immunohistochemistry
Sections were deparaffinized in hot xylene. Rehydration
of slides was performed by immersing slides in descend-
ing alcohol concentrations and then washed in distilled
water. The sections were rinsed in two washes of phos-
phate-buffered saline for 5 minutes each (PBS; pH 7.4).
For staining with mdm2 antibody, the sections were
microwave antigen retrieved with citrate buffer solution
(pH 4.8 for 15 minutes). P27 Kip-1 and bcl-2 antibodies
required antigen retrieval by microwave processing in 0.2
M glycine buffer (Glyca, pH 6.2 ± 0.2, for 15 min.). Sec-
tions were again rinsed in two washes of PBS. Endogenous
peroxidase activity was blocked with 3% hydrogen perox-
ide in water. The primary antibodies anti-mdm2, anti-p27
Kip-1, and anti-bcl-2 were applied and the slides were incu-
bated in a humid chamber overnight at room tempera-
ture. The sections were then washed in PBS. The secondary
(Link) antibody (Biotinylated anti-mouse IgG, dilution
1:25) was then applied and the slides were incubated for
20 minutes at room temperature. After washing with PBS,
the slides were incubated with peroxidase-labelled
streptavidin complex for 20 minutes at room temperature,
and then washed with PBS. The slides were then incu-
bated with a solution of 3% diamino-benzidine (DAB) as
the chromogen for 20 minutes. Finally, the tissues were
lightly counter stained with Mayer's Haematoxylin and
mounted with DPX permanent mounting medium.
Assessment
In this study, the immunostaining of each antibody was
assessed in 5 serial sections from each specimen. For
mdm2, tumor cells were considered immunopositive
when they displayed a brownish nuclear and/or cytoplas-
mic immunoreactivity, p27 Kip-1  immunostaining was
considered positive when tumor cells showed a nuclear
immunoreactivity while bcl-2 was considered positive if
the tumor cells showed cytoplasmic or perinuclear locali-
zation of immunoreactivity.
Results and discussion
Mdm2 Immunohistolochemical Results
All specimens were positively stained with mdm2. Most of
the neoplastic epithelial cells forming papillae showed
cytoplasmic immunopositivity, both the cuboidal basal
cells and the columnar luminal cells (fig. 1), while goblet
cells were immunonegative (fig. 2).
P27Kip-1 Immunohistolochemical Results
All specimens showed positive immunoreactivity. Both
layers of the neoplastic epithelium (basal and columnar
cells) revealed positive nuclear immunostaining, sur-
rounded by a negatively stained stroma (fig. 3). Basal epi-
thelial cells showed a faint immunppositive reaction.
However, a combination of cytoplasmic and nuclearDiagnostic Pathology 2009, 4:14 http://www.diagnosticpathology.org/content/4/1/14
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staining was observed (fig. 4). Myoepithelial cells were
negatively stained (fig. 4).
Bcl-2 Immunohistolochemical Results
Eighteen out of 20 cases (90%) were positively stained.
Both layers of the neoplastic epithelium (basal and lumi-
nal cells) showed positive immunoreactivity, with cyto-
plasmic localization, surrounded by a negatively stained
stroma (fig. 5). Few basal cells were faintly positive while
others were immunonegative. Myoepithelial and goblet
cells were also negative (fig. 6). Areas of budding in epi-
thelial cells showed immunopositive reaction (fig. 6).
Discussion
This study was aimed to investigate the immunoexpres-
sion of mdm2 oncoprotein, p27Kip1 tumor suppressor
protein as well as bcl-2 anti-apoptotic protein in
Warthin's tumor as a trial to clarify the possible role of
these families in the pathogenesis of this unique tumor of
salivary glands.
immunopositive epithelial cells forming papillary growth Figure 1
immunopositive epithelial cells forming papillary 
growth. The C.T. stroma is negative (anti-mdm2 ×100).
Higher magnification of figure 1 showing cytoplasmic immu- nopositivity in both basal and luminal cells Figure 2
Higher magnification of figure 1 showing cytoplasmic 
immunopositivity in both basal and luminal cells. 
Goblet cells are immunonegative (anti-mdm2 ×200).
immunopositive neoplastic epithelial cells forming papillary  growth Figure 3
immunopositive neoplastic epithelial cells forming 
papillary growth. The C.T. stroma is negative (anti-p27 
×200).
Higher magnification of figure 3 showing intense immunore- activity in both layers of neoplastic epithelial cells Figure 4
Higher magnification of figure 3 showing intense 
immunoreactivity in both layers of neoplastic epithe-
lial cells. Some cells are showing both nuclear and cytoplas-
mic immunopositivity (anti-p27 ×400).Diagnostic Pathology 2009, 4:14 http://www.diagnosticpathology.org/content/4/1/14
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Earlier studies focused on the analysis of p53 gene in
tumors of the salivary glands; however the connection
between salivary gland carcinogenesis and the mdm2
oncoprotein was still elusive [8]. Some authors demon-
strated that not only p53 gene is a potential target in neo-
plastic transformation, but also genes involved in the
regulation of its function since mdm2 can potently regu-
late p53, and functions as an oncogene in the process of
cell transformation [20]. Some authors considered both
nuclear and cytoplasmic staining or exclusively cytoplas-
mic staining as positive results [21], and this was chosen
for assessment of immunopositive reaction of mdm2 in
this study, because a strong evidence is now available that
mdm2 is an RNA binding protein that can shuttle
between the nucleus and the cytoplasm [22], and both
mdm2 and p53 proteins contain a nuclear-import and
nuclear-export signals (NES) that enable them to be
directed into the nucleus and out again towards the cyto-
plasm [7]. This NES of mdm2 is essential for p53 degrada-
tion by interacting with cytoplasmic proteasomes, where
p53 is specifically degraded [23].
Overexpression of mdm2 protein in glandular epithelium
leads to abnormal development, altered histological
structure and eventually to overt epithelial neoplasia [21].
Mdm2 is considered an oncoprotein through its p53-
dependent and p53-independent functions, therefore the
expression of mdm2 in both epithelial cell layers in
Warthin's tumor might indicate a high proliferation rate
of this tumor.
But since Warthin's tumor is reported to be a benign, non-
aggressive tumor [24], therefore the increase amount of
mdm2 in these lesions may be attributed to the expression
of a smaller protein of the mdm2 molecule called p74/76
that binds to p53 and doesn't inhibit its action or even
preserve its presence rather than degrade it. This unique
role of p74/76 is mediated through binding with p90
leading to inhibition of its function.
Brown et al [25] stated that the human oncoprotein
mdm2 arrests the cell cycle and elimination of its cell cycle
inhibitory function induces tumorigenesis. They attrib-
uted this finding to the dual role of mdm2, which suggests
that full-length mdm2 can induce growth arrest in some
cell lines, including some normal cells. Only elimination
or inactivation of the mdm2-induced G0/G1 arrest may
contribute to one of the steps of tumorigenesis. Some
tumor-derived cells are partially insensitive to the mdm2-
mediated cell cycle inhibition and mdm2 can be stably
overexpressed in these tumor cells. This dual function of
mdm2, suggested by other investigators [26], might
explain the high level of expression of mdm2 in Warthin's
tumor.
The dual role of mdm2 could depend on the level of
mdm2 expressed in the individual cell and the balance of
some positive and negative regulators of the cell cycle
which is critical for control of cell proliferation and small
differences in the levels of any of these proteins may mean
large differences in cell activities [26].
Immunohistochemical results of the present study also
revealed that Warthin's tumour expressed a high level of
Positive cytoplasmic immunostaining of luminal cells and few  basal epithelial cells Figure 5
Positive cytoplasmic immunostaining of luminal cells 
and few basal epithelial cells. Myoepithelial cells are 
immunonegative. The surrounding stroma is also negative 
(anti-bcl2 ×200).
Higher magnification of figure 5 showing intense positive  cytoplasmic immunostaining of luminal cells while few basal  epithelial cells are faintly positive Figure 6
Higher magnification of figure 5 showing intense pos-
itive cytoplasmic immunostaining of luminal cells 
while few basal epithelial cells are faintly positive. 
(anti-bcl2 ×400).Diagnostic Pathology 2009, 4:14 http://www.diagnosticpathology.org/content/4/1/14
Page 6 of 7
(page number not for citation purposes)
p27Kip1 and bcl-2, with p27Kip1 immunopositivity detected
in all 20 cases, while 18/20 cases were bcl-2 immunopos-
itive. P27Kip1 protein was detected in both layers of the
neoplastic epithelium (basal and luminal) indicating the
low proliferation rate of these cells. The more faintly
stained basal cells indicated their higher rate of prolifera-
tion [27].
On the other hand, bcl-2 immunopositivity was also
detected in both layers of the neoplastic epithelium. Areas
of budding were also immunopositive indicating the
attempt of this protein to maintain the survival of these
more proliferative cells and that these epithelial cells
might play a role as stem cells [28].
The mutual presence of p27Kip1 and bcl-2 proteins in these
same cells indicated the protection of these slowly prolif-
erating cells from apoptosis to maintain their survival.
This conclusion may put forward that mdm2 in this lesion
is not acting as oncogene, but rather act as a tumor sup-
pressor gene or a smaller protein is expressed. High levels
of p27Kip1 favor apoptosis, which can be counteracted by
other regulatory factors as bcl-2. It was observed that ele-
vated bcl-2 expression did confer significant protection
against p27Kip1-mediated apoptosis [27]. Bcl-2 protein
promotes cell survival in slowly growing tumors and this
might decreased the rate of acquiring further defects.
Therefore, bcl-2 expression appears to be associated with
less aggressive tumor behavior [28].
Bcl-2-Immunonegativity noted in only 2 out of 20 cases of
the present study might indicated failure of bcl-2 to block
apoptosis in certain circumstances such as apoptosis
induced by cytotoxic T-lymphocytes [18], a finding that
might indicated a reactive nature of the lymphoid tissue in
Warthin's tumor [29].
Some lesions showed proliferating bud at a part of the
neoplastic epithelium, that might suggest an aggressive
clinical behavior of this lesion or that this lesion may turn
into malignancy, however the result of this study attesting
the positivity of the neoplastic epithelium for the three
antibody used, it is suggested that the proliferating bud is
only a part of the non-aggressive lesion as p27Kip1 and
mdm2, in this lesion, act as tumor suppressor proteins
while the bcl-2 would in part protect these slowly prolif-
erating cells from apoptosis. Therefore, it could be esti-
mated that Warthin's tumor is slowly but continuously
proliferating tumor.
Conclusion
￿ Mdm-2 could play a tumor-suppressor role that
might be implicated with the benign behavior of
Warthin's tumor.
￿ Mutual expression of both p27Kip1 and bcl-2 sug-
gested a protective role of these slowly proliferating
cells from apoptosis to maintain their survival but not
to increase their malignant potentiality.
￿ Elevated bcl-2 expression in Warthin's tumor sug-
gests a possible protection against p27Kip1-mediated
apoptosis.
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